معرفی
Samuel Wilkinson, MD, is an Associate Professor of Psychiatry at Yale School of Medicine and Associate Director of the Yale Depression Research Program. His research focuses on improving access to evidence-based therapies for depression and mood disorders, with a focus on electroconvulsive therapy (ECT), ketamine, and neuroplasticity-based interventions. He holds appointments in multiple centers, including the Center for Brain & Mind Health and the Neuroscience Research Training Program.
Education:
- MD: Johns Hopkins University School of Medicine (2012)
- BS in Mechanical Engineering: Brigham Young University (2008)
- Residency: Yale School of Medicine (2016)
Research Interests: Dr. Wilkinson investigates relapse prevention strategies for severe depression, the clinical use of ketamine, and the impact of cannabis on mental health outcomes. He emphasizes patient-centered outcomes research and collaborates with experts like Gerard Sanacora and John Krystal.
Recent Work: His 2025 studies compare ECT and ketamine efficacy, while 2023 work explores ketamine's neurobiological mechanisms and safety profiles. He has authored over 40 peer-reviewed publications and contributed to clinical guidelines for psychedelic therapies.
Awards:
- New Investigator Award (2019)
- NARSAD Young Investigator Award (2017)
- Top Advancements & Breakthroughs (2017)
Labs/Teams: Active in the Yale Depression Research Program and the Psychedelic Research Group, advancing translational research in rapid-acting antidepressants.